Markets:

Overview

News

Currencies

International

Treasuries

Neurocrine Biosciences, Inc. - Common Stock (NQ:NBIX)

157.50 +1.99 (+1.28%)

Streaming Delayed Price Updated: 12:08 PM EST, Dec 8, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Neurocrine Biosciences, Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases ↗

August 05, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Neurocrine Biosciences Shares Jump After Raising Ingrezza Sales Guidance ↗

August 05, 2022

Via Benzinga

Neurocrine Biosciences Shelves Key Drug; Will It Overshadow The Earnings Beat? ↗

August 04, 2022

Neurocrine says the essential tremor drug didn't hit its goals in a key study.

Via Investor's Business Daily

Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate ↗

August 04, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Analyst Ratings For Neurocrine Biosciences ↗

February 01, 2022

Within the last quarter, Neurocrine Biosciences (NASDAQ:NBIX) has observed the following analyst ratings:

Via Benzinga

Dow Jones Giant Amgen Leads 5 Stocks To Watch Near Buy Points ↗

July 23, 2022

Dow Jones giant Amgen headlines five stocks to watch setting near buy points or key support levels that may offer early entries.

Via Investor's Business Daily

Needham Previews Neurocrine's Upcoming Mid-Stage Data from Essential Tremor Study ↗

July 11, 2022

Needham previews the upcoming Phase 2 data readout for Neurocrine Biosciences Inc's (NASDAQ: NBIX) NBI-827104, a t-type calcium channel blocker in essential tremor (ET), by mid-2022.

Via Benzinga

Neurocrine Biosciences Earnings Perspective: Return On Capital Employed ↗

May 19, 2022

According to Benzinga Pro, during Q1, Neurocrine Biosciences (NASDAQ:NBIX) earned $13.90 million, a 290.41% increase from the preceding quarter. Neurocrine Biosciences's sales decreased to $310.60...

Via Benzinga

The Daily Biotech Pulse: FDA Orphan Drug Tags For Neurocrine, Editas Candidates; Sale of BridgeBio's PRV; RMAT Designation For PolarityTE's Product ↗

May 13, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Neurocrine Biosciences: Q1 Earnings Insights ↗

May 04, 2022

Neurocrine Biosciences (NASDAQ:NBIX) reported its Q1 earnings results on Wednesday, May 4, 2022 at 07:30 AM. Here's what investors need to know about the announcement.

Via Benzinga

Neurocrine Biosciences Q1 2022 Earnings Conference Call On May 4, 2022 At 08:00 AM ET ↗

April 25, 2022

Neurocrine Biosciences (NASDAQ:NBIX) will host a conference call at 08:00 AM ET on May 4, 2022, to discuss Q1 2022 earnings results.

Via Benzinga

What 8 Analyst Ratings Have To Say About Neurocrine Biosciences ↗

April 04, 2022

Neurocrine Biosciences (NASDAQ:NBIX) has observed the following analyst ratings within the last quarter:

Via Benzinga

The Daily Biotech Pulse: Sanofi-IGM Ink Antibody Drug Collaboration; NeoGenomics Sinks On CEO Departure, Q1 Warning; Decision Day For Akebia ↗

March 29, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 3, 2022 ↗

March 03, 2022

Upgrades For Douglas Emmett Inc (NYSE:DEI), Evercore ISI Group upgraded the previous rating of In-Line to Outperform. For the fourth quarter, Douglas Emmett had an EPS of $0.48,...

Via Benzinga

Where Neurocrine Biosciences Stands With Analysts ↗

February 25, 2022

Neurocrine Biosciences (NASDAQ:NBIX) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For February 25, 2022 ↗

February 25, 2022

Upgrades According to 86 Research, the prior rating for NetEase Inc (NASDAQ:NTES) was changed from Hold to Buy. For the fourth quarter, NetEase had an EPS of $1.56,...

Via Benzinga

Looking Into Neurocrine Biosciences's Return On Capital Employed ↗

February 14, 2022

Benzinga Pro data, Neurocrine Biosciences (NASDAQ:NBIX) reported Q4 sales of $312.00 million. Earnings fell to a loss of $7.30 million, resulting in a 132.44% decrease from last quarter.

Via Benzinga

Why Neurocrine Biosciences Are Trading Higher Today? ↗

February 11, 2022

Neurocrine Biosciences Inc (NASDAQ: NBIX) reported Q4 Ingrezza sales of $301 million, +25% Y/Y, with total prescriptions up 32% Overall sales increased $312.0 million...

Via Benzinga

The Daily Biotech Pulse: Adcom Recommends Additional Trials For Lilly's Partnered Cancer Drug, Novavax Touts Pediatric Vaccine Data, TC Biopharm IPO ↗

February 11, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adcom Rules That Lilly May Have To Conduct Additional Studies For Co-...

Via Benzinga

Recap: Neurocrine Biosciences Q4 Earnings ↗

February 11, 2022

Neurocrine Biosciences (NASDAQ:NBIX) reported its Q4 earnings results on Friday, February 11, 2022 at 07:30 AM. Here's what investors need to know about the announcement. Earnings Neurocrine...

Via Benzinga

Earnings Scheduled For February 11, 2022 ↗

February 11, 2022

Companies Reporting Before The Bell • Mr. Cooper Group (NASDAQ:COOP) is expected to report quarterly earnings at $1.22 per share on revenue of $551.60 million.

Via Benzinga

A Preview Of Neurocrine Biosciences's Earnings ↗

February 10, 2022

Neurocrine Biosciences (NASDAQ:NBIX) is set to give its latest quarterly earnings report on Friday, 2022-02-11. Here's what investors need to know before the announcement. Analysts estimate that...

Via Benzinga

The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, IPOs And More ↗

February 06, 2022

Biotech stocks managed to close the week ending Feb. 4 with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid negative reaction to some big...

Via Benzinga

10 Biggest Price Target Changes For Tuesday ↗

January 18, 2022

Keybanc raised J.B. Hunt Transport Services, Inc. (NASDAQ:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For January 18, 2022 ↗

January 18, 2022

Upgrades Canaccord Genuity upgraded the previous rating for Fortuna Silver Mines Inc (NYSE:

Via Benzinga

Xenon Receives $15M Regulatory Milestone Under Epilepsy Pact With Neurocrine ↗

January 12, 2022

Xenon Pharmaceuticals Inc's (NASDAQ: XENE) collaboration to develop treatments for epilepsy with Neurocrine Biosciences Inc (NASDAQ: NBIX) achieved a regulatory...

Via Benzinga

Analyst Ratings For Neurocrine Biosciences ↗

January 07, 2022

Over the past 3 months, 9 analysts have published their opinion on Neurocrine Biosciences (NASDAQ:

Via Benzinga

The Daily Biotech Pulse: Glaukos Gets FDA Nod, Neurocrine Preannounces Soft Ingrezza Sales, 3 IPOs ↗

January 07, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Hepion's Lead NASH Drug Candidate Gets The Non-Proprietary Name...

Via Benzinga

Expert Ratings For Neurocrine Biosciences ↗

December 08, 2021

Neurocrine Biosciences (NASDAQ:NBIX) has observed the following analyst rat...

Via Benzinga

The Daily Biotech Pulse: Valneva Strikes Deal To Supply COVID Vaccine to Bahrain, TherapeuticsMD & Amneal Settle Patent Lawsuit, Reata Awaits Adcom ↗

December 08, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus EyePoint Announces Commercialization Agreement For Dexycu To Treat Post-...

Via Benzinga

Topics Intellectual Property Lawsuit

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.